Company Overview
Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognise the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to learn, adapt, and our tenacity to overcome barriers, together.
Opportunity Overview
Rhythm is seeking an experienced Medical Director responsible for the UK & Ireland, based in the UK. This role is central to shaping and executing scientific, strategic and operational excellence in the region with a strong focus on pre-launch planning, team development and stakeholder engagement.
The ideal candidate will have a sound medical background, deep scientific insight and strong business acumen. As a qualified ABPI final signatory, they will serve as a subject matter expert and trusted leader, driving Rhythm’s mission to transform the lives of patients and their families living with rare neuroendocrine diseases.
Reporting to the General Manager for the UK & Ireland you will collaborate closely with the commercial and International Medical Affairs team.
Responsibilities and Duties
Qualifications and Skills
This role will be home-office based. Candidates applying must be located in a centralized UK location and have easy access to transportation and airports.
More about Rhythm
Our lead asset, IMCIVREE® (setmelanotide), is a precision medicine designed to treat hyperphagia, an insatiable, pathological hunger characterized by abnormal food-seeking behaviors, and early- or rapid-onset severe obesity caused by an impairment of a pathway in the hypothalamus called the melanocortin-4 receptor (MC4R) pathway. IMCIVREE® is the first and only approved therapy for certain rare MC4R pathway diseases in the United States, Europe, Great Britain and several other countries. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in MC4R pathway diseases, including a Phase 3 trial for acquired hypothalamic obesity. In addition, we are leveraging our extensive genetic database, global network of researchers, a track record of regulatory successes and global commercial infrastructure to develop a full portfolio of treatment options to patients struggling with hyperphagia and severe obesity and ensuring they get the treatment that is right for them.
We continue to advance care and precision medicines that address rare diseases. We are focused on expanding access to IMCIVREE® to reach more patients and developing novel therapies for other rare neuroendocrine diseases, including congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Read Full Description